| | Business Summary | | Martek
Biosciences
Corporation
develops,
manufactures
and
sells
products
primarily
derived
from
microalgae.
The
Company
is
currently
selling
nutritional
supplements
for
infant
formula
and
other
nutritional
product
applications,
products
for
use
in
basic
structural
molecular
research
and
structure-based
drug
design
and
diagnostic
products.
Martek
is
developing
additional
nutritional
and
diagnostic
products
as
well
as
pharmaceutical
discovery
technologies.
A
portion
of
its
research
and
development
efforts
is
performed
under
various
contracts
and
grants.
The
Company
sells
to
a
broad
range
of
companies
and
academic
and
research
institutions
worldwide. | | More
from
Market Guide: Expanded
Business Description |
| | Financial Summary | | MATK
develops,
manufactures
and
sells
products
from
microalgae,
including
nutritional
supplements
for
infant
formula
and
other
nutritional
products,
and
products
for
use
in
basic
structural
molecular
research
and
structure
based
drug
design.
For
the
six
months
ended
4/30/01,
revenues
rose
81%
to
$7.5
million.
Net
loss
fell
14%
to
$6.8
million.
Revenues
reflect
increased
nutritional
product
sales.
Net
loss
was
partially
offset
by
higher
corporate
expenses. | | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Henry Linsert, Jr., 60
Chairman
and CEO | $302K | -- | Richard Radmer, Ph.D., 58
Pres,
CSO | 160K | -- | Peter Buzy, 41
CFO
and Treasurer | -- | $86K | George Barker, 61
Sr.
VP, Gen. Counsel, Sec. | -- | -- | Jerome Keller, 58
Sr.
VP, Sales & Marketing | 196K | -- | | Dollar
amounts are as of 31-Oct-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors:
Expanded
List, Bios,
Compensation,
Options
|
|
![[one-year price graph]](http://chart.yahoo.com/c/0b/m/matk.gif)